CathWorks Announces the Completion of Enrollment for Landmark ALL-RISE Randomized Controlled Trial | PR Newswire [Video]

ALL-RISE Study Included Over 1,924 Patients in 59 Sites Across 

North America, Asia, Europe and the Middle East

, /PRNewswire/ — CathWorks, a global leader in medical device digital health innovations, announced today the successful completion of enrollment of the Advancing Cath Lab Results with FFRangio Coronary Physiology Assessment (ALL-RISE) randomized controlled trial (RCT). This landmark study represents a significant milestone in the field of interventional cardiology, evaluating the clinical and economic benefits of the CathWorks FFRangio^® System in diagnosing and treating coronary artery disease (CAD), offering potentially groundbreaking evidence that could redefine the standard of care.

The ALL-RISE Study included over 1,924 patients across 59 sites in North America, Asia, Europe and the Middle East. Participants presenting with coronary stenoses of intermediate significance and requiring physiology assessment were randomized to receive either FFRangio-guided treatment or …